Continuous Infusion of Recombinant FIX (BeneFIX) During Herniotomy in an Infant

Perioperative prophylaxis or treatment of severe bleedings in patients with hemophilia A or B and von Willebrand disease requires substitution of coagulation factors for a longer period of time. Recently continuous infusion (CI) has been used as an alternative to bolus injections to avoid fluctuations in factor plasma levels [1,7]. This mode of replacement therapy was found to decrease the consumption of factor concentrates by between 20% and 50% resulting in a reduction of treatment costs. So far, data with FIX concentrates and CI are available for plasma-derived FIX (pdFIX) only [1,6,7,8]. Here we report on an infant with severe hemophilia B undergoing herniotomy. CI of recombinant FIX (BeneFIX, Baxter, Hyland Immuno Division) was performed to cover surgery.